<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00310323</url>
  </required_header>
  <id_info>
    <org_study_id>OSAS 003-03</org_study_id>
    <nct_id>NCT00310323</nct_id>
  </id_info>
  <brief_title>Hepatic Drug Biotransformation in Children With Obstructive Sleep Apnea</brief_title>
  <official_title>Effect of Chronic Intermittent Nocturnal Hypoxia on Hepatic Drug Biotransformation in Children With Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine the effect of chronic nighttime low oxygen
      saturations on selected body systems (liver) that break down drugs in children with
      obstructive sleep apnea syndrome (OSAS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the effect of chronic intermittent nocturnal
      hypoxia on selected hepatic drug-metabolizing enzyme systems in children with OSAS. The
      specific aims are to evaluate the activities of cytochrome P450 (CYP)1A2,
      N-acetyltransferase-2 (NAT-2), xanthine oxidase (XO)and CYP2D6 in children with OSAS and to
      determine the effect of OSAS treatment on the activities of these enzyme systems.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">February 2006</completion_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Caffeine urinary molar ratio</measure>
    <time_frame>Pre and post T&amp;A</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dextromethorphan urinary molar ratio</measure>
    <time_frame>Pre and post T&amp;A</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children with OSAS identified via sleep study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextromethorphan</intervention_name>
    <description>0.5 mg/kg (maximum 30 mg)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine</intervention_name>
    <description>Administered as 4 ounces of Coca-Cola</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children ages 4 to 16 years with suspected uncomplicated OSAS

        Exclusion Criteria:

          -  Children with complicated OSAS (craniofacial abnormalities, neuromuscular disorders)

          -  Children who are receiving medications known to induce or inhibit hepatic CYP1A2,
             NAT-2, XO, CYP2D6 or CYP3A4 activity

          -  Children who are exposed to second hand smoke for greater than 8 hours per day.

          -  Children with hypersensitivity to caffeine or dextromethorphan

          -  Children who are receiving corticosteroids or thyroid hormone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Jayne Kennedy, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2006</study_first_submitted>
  <study_first_submitted_qc>March 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2006</study_first_posted>
  <last_update_submitted>March 17, 2009</last_update_submitted>
  <last_update_submitted_qc>March 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Mary Jayne Kennedy, Pharm.D.</name_title>
    <organization>Virginia Commonwealth University</organization>
  </responsible_party>
  <keyword>sleep apnea</keyword>
  <keyword>phenotyping</keyword>
  <keyword>cytochrome P450</keyword>
  <keyword>drug metabolism</keyword>
  <keyword>child</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

